Literature DB >> 21145801

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.

Christian Markus Lange1, Jörg Bojunga, Elizabeth Ramos-Lopez, Michael von Wagner, Angela Hassler, Johannes Vermehren, Eva Herrmann, Klaus Badenhoop, Stefan Zeuzem, Christoph Sarrazin.   

Abstract

BACKGROUND & AIMS: Vitamin D is an important immune modulator and preliminary data indicated an association between vitamin D deficiency and sustained virologic response (SVR) rates in hepatitis C virus (HCV) genotype 1 patients. We, therefore, performed a comprehensive analysis on the impact of vitamin D serum levels and of genetic polymorphisms with functional relevance within the vitamin D cascade on chronic hepatitis C and its treatment.
METHODS: Vitamin D serum levels, genetic polymorphisms within the vitamin D receptor and 1α-hydroxylase were determined in a cohort of 468 HCV genotype 1, 2, and 3 infected patients who were treated with interferon-alfa based regimens.
RESULTS: Chronic hepatitis C was associated with a high incidence of severe vitamin D deficiency compared to controls (25(OH)D(3)<10 ng/ml in 25% versus 12%, p<0.00001). 25(OH)D(3) deficiency correlated with SVR in HCV genotype 2 and 3 patients (50% and 81% SVR for patients with and without severe vitamin D deficiency, respectively, p<0.0001). In addition, the CYP27B1-1260 promoter polymorphism rs10877012 had substantial impact on 1,25-dihydroxyvitamin D serum levels (72, 61, and 60 pmol/ml for rs10877012 AA, AC, and CC, respectively, p=0.04) and on SVR rates in HCV genotype 1, 2, and 3 infected patients (77% and 65% versus 42% for rs10877012 AA, AC, and CC, respectively, p=0.02).
CONCLUSIONS: Chronic hepatitis C virus infection is associated with vitamin D deficiency. Reduced 25-hydroxyvitamin D levels and CYP27B1-1260 promoter polymorphism leading to reduced 1,25-dihydroxyvitamin D levels are associated with failure to achieve SVR in HCV genotype 1, 2, and 3 infected patients.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21145801     DOI: 10.1016/j.jhep.2010.08.036

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  85 in total

Review 1.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

2.  25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors:  Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 3.  Association between vitamin D and hepatitis C virus infection: a meta-analysis.

Authors:  Livia Melo Villar; José Antonio Del Campo; Isidora Ranchal; Elisabeth Lampe; Manuel Romero-Gomez
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 4.  Novel therapies for hepatitis C - one pill fits all?

Authors:  Michael P Manns; Thomas von Hahn
Journal:  Nat Rev Drug Discov       Date:  2013-06-28       Impact factor: 84.694

5.  The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.

Authors:  Anu Osinusi; Susanna Naggie
Journal:  Eur Gastroenterol Hepatol Rev       Date:  2012

6.  Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.

Authors:  Assy Nimer; Abu Mouch
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

7.  Could vitamin d supplementation benefit patients with chronic liver disease?

Authors:  Ilaria Barchetta
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

8.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

9.  Serum vitamin D₃ does not correlate with liver fibrosis in chronic hepatitis C.

Authors:  Yan Ren; Mei Liu; Jing Zhao; Feng Ren; Yu Chen; Jun-Feng Li; Jing-Yun Zhang; Feng Qu; Jin-Lan Zhang; Zhong-Ping Duan; Su-Jun Zheng
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males.

Authors:  D L White; S Tavakoli-Tabasi; F Kanwal; D J Ramsey; A Hashmi; J Kuzniarek; P Patel; J Francis; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2013-05-26       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.